Expression mechanism and clinical significance of absent in melanoma 2 in liver diseases

Yingyu LE; Rongzhen ZHANG; Tingshuai WANG; Ningfang CHEN; Dewen MAO

doi:10.3969/j.issn.1001-5256.2021.10.049

Volume 37 Issue 10

Oct. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(10): 2488-2492

PDF( 1911 KB)

Expression mechanism and clinical significance of absent in melanoma 2 in liver diseases

DOI: 10.3969/j.issn.1001-5256.2021.10.049

1.
Graduate School, Guangxi University of Chinese Medicine, Nanning 530222, China
2a.
First Ward of Liver Diseases, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, China
2b.
First Ward of Spleen and Stomach, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, China

Research funding:

General Project of National Natural Science Foundation of China (81774236);

National Natural Science Foundation of China (81960841);

Natural Science Foundation of Guangxi Province (2018GXNSFAA281096);

Guangxi Science and Technology Plan Project-Guangxi Science and Technology Base and Talent Special Project (GK AD17129001)

Received Date: 2021-03-03
Accepted Date: 2021-03-15
Published Date: 2021-10-20

Abstract

Abstract

Absent in melanoma 2 (AIM2) is a cytoplasmic double-stranded DNA (dsDNA) sensing protein that can recognize the dsDNA released during cell disturbance and pathogen invasion and trigger the activation of inflammasome cascade. Activation of inflammasomes leads to the maturation and release of inflammatory cytokines (interleukin-1β and interleukin-18), induces pyroptosis, and initiate innate immune response. Among these inflammasomes, AIM2 and its mechanism of action and clinical significance in liver diseases has become a research hotspot at present. This article summarizes and discusses the importance of AIM2 in the pathogenesis of various liver diseases including nonalcoholic fatty liver disease, hepatitis B virus infection, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma, so as to provide new ideas and a reference for clinical treatment.
- Liver Diseases,
- Inflammation,
- Inflammasomes

FullText(HTML)

References(42)

References

[1]	NEWTON K, DIXIT VM. Signaling in innate immunity and inflammation[J]. Cold Spring Harb Perspect Biol, 2012, 4(3): a006049. DOI: 10.1101/cshperspect.a006049.
[2]	TAKEUCHI O, AKIRA S. Pattern recognition receptors and inflammation[J]. Cell, 2010, 140(6): 805-820. DOI: 10.1016/j.cell.2010.01.022.
[3]	SZABO G, PETRASEK J. Inflammasome activation and function in liver disease[J]. Nat Rev Gastroenterol Hepatol, 2015, 12(7): 387-400. DOI: 10.1038/nrgastro.2015.94.
[4]	SHI C, YANG H, ZHANG Z. Involvement of nucleotide-binding oligomerization domain-like receptor family pyrin domain containing 3 inflammasome in the pathogenesis of liver diseases[J]. Front Cell Dev Biol, 2020, 8: 139. DOI: 10.3389/fcell.2020.00139.
[5]	XU T, DU Y, FANG XB, et al. New insights into Nod-like receptors (NLRs) in liver diseases[J]. Int J Physiol Pathophysiol Pharmacol, 2018, 10(1): 1-16. http://www.ijppp.org/files/ijppp0073857.pdf
[6]	SZABO G, CSAK T. Inflammasomes in liver diseases[J]. J Hepatol, 2012, 57(3): 642-654. DOI: 10.1016/j.jhep.2012.03.035.
[7]	LUAN J, JU D. Inflammasome: A double-edged sword in liver diseases[J]. Front Immunol, 2018, 9: 2201. DOI: 10.3389/fimmu.2018.02201.
[8]	JIN T, PERRY A, JIANG J, et al. Structures of the HIN domain: DNA complexes reveal ligand binding and activation mechanisms of the AIM2 inflammasome and IFI16 receptor[J]. Immunity, 2012, 36(4): 561-571. DOI: 10.1016/j.immuni.2012.02.014.
[9]	WANG B, YIN Q. AIM2 inflammasome activation and regulation: A structural perspective[J]. J Struct Biol, 2017, 200(3): 279-282. DOI: 10.1016/j.jsb.2017.08.001.
[10]	MORRONE SR, MATYSZEWSKI M, YU X, et al. Assembly-driven activation of the AIM2 foreign-dsDNA sensor provides a polymerization template for downstream ASC[J]. Nat Commun, 2015, 6: 7827. DOI: 10.1038/ncomms8827.
[11]	HOSS F, RODRIGUEZ-ALCAZAR JF, LATZ E. Assembly and regulation of ASC specks[J]. Cell Mol Life Sci, 2017, 74(7): 1211-1229. DOI: 10.1007/s00018-016-2396-6.
[12]	LIU X, ZHANG Z, RUAN J, et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores[J]. Nature, 2016, 535(7610): 153-158. DOI: 10.1038/nature18629.
[13]	BROZ P, DIXIT VM. Inflammasomes: Mechanism of assembly, regulation and signalling[J]. Nat Rev Immunol, 2016, 16(7): 407-420. DOI: 10.1038/nri.2016.58.
[14]	YANG J, LIU Z, XIAO TS. Post-translational regulation of inflammasomes[J]. Cell Mol Immunol, 2017, 14(1): 65-79. DOI: 10.1038/cmi.2016.29.
[15]	LIU T, TANG Q, LIU K, et al. TRIM11 suppresses AIM2 inflammasome by degrading AIM2 via p62-dependent selective autophagy[J]. Cell Rep, 2016, 16(7): 1988-2002. DOI: 10.1016/j.celrep.2016.07.019.
[16]	KHARE S, RATSIMANDRESY RA, de ALMEIDA L, et al. The PYRIN domain-only protein POP3 inhibits ALR inflammasomes and regulates responses to infection with DNA viruses[J]. Nat Immunol, 2014, 15(4): 343-353. DOI: 10.1038/ni.2829.
[17]	LI H, WANG J, WANG J, et al. Structural mechanism of DNA recognition by the p202 HINa domain: Insights into the inhibition of Aim2-mediated inflammatory signalling[J]. Acta Crystallogr F Struct Biol Commun, 2014, 70(Pt 1): 21-29. DOI: 10.1107/S2053230X1303135X.
[18]	YIN Q, SESTER DP, TIAN Y, et al. Molecular mechanism for p202-mediated specific inhibition of AIM2 inflammasome activation[J]. Cell Rep, 2013, 4(2): 327-339. DOI: 10.1016/j.celrep.2013.06.024.
[19]	DIEHL AM, FARPOUR-LAMBERT NJ, ZHAO L, et al. Why we need to curb the emerging worldwide epidemic of nonalcoholic fatty liver disease[J]. Nat Metab, 2019, 1(11): 1027-1029. DOI: 10.1038/s42255-019-0140-x.
[20]	CSAK T, PILLAI A, GANZ M, et al. Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis[J]. Liver Int, 2014, 34(9): 1402-1413. DOI: 10.1111/liv.12537.
[21]	TANG D, KANG R, ZEH HJ 3rd, et al. High-mobility group box 1, oxidative stress, and disease[J]. Antioxid Redox Signal, 2011, 14(7): 1315-1335. DOI: 10.1089/ars.2010.3356.
[22]	GANZ M, CSAK T, SZABO G. High fat diet feeding results in gender specific steatohepatitis and inflammasome activation[J]. World J Gastroenterol, 2014, 20(26): 8525-8534. DOI: 10.3748/wjg.v20.i26.8525.
[23]	GONG Z, ZHANG X, SU K, et al. Deficiency in AIM2 induces inflammation and adipogenesis in white adipose tissue leading to obesity and insulin resistance[J]. Diabetologia, 2019, 62(12): 2325-2339. DOI: 10.1007/s00125-019-04983-x.
[24]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[25]	PANG XQ, LI XH, MO ZS, et al. Expression of factor 2 deficiency in patients with chronic hepatitis B and its correlation with the degree of disease[J/CD]. Chin J Exp Clin Infect Dis (Electronic Edition), 2015, 9(3): 326-330. DOI: 10.3877/cma.j.issn.1674-1358.2015.03.007. 庞秀青, 李新华, 莫志硕, 等. 慢性乙型肝炎患者肝组织中黑色素瘤缺乏因子2表达与病变程度的相关性[J/CD]. 中华实验和临床感染病杂志(电子版), 2015, 9(3): 326-330. DOI: 10.3877/cma.j.issn.1674-1358.2015.03.007.
[26]	WU DL, XU GH, LU SM, et al. Correlation of AIM2 expression in peripheral blood mononuclear cells from humans with acute and chronic hepatitis B[J]. Hum Immunol, 2013, 74(5): 514-521. DOI: 10.1016/j.humimm.2013.01.022.
[27]	CHEN H, HE G, CHEN Y, et al. Differential activation of NLRP3, AIM2, and IFI16 inflammasomes in humans with acute and chronic hepatitis B[J]. Viral Immunol, 2018, 31(9): 639-645. DOI: 10.1089/vim.2018.0058.
[28]	HAN Y, CHEN Z, HOU R, et al. Expression of AIM2 is correlated with increased inflammation in chronic hepatitis B patients[J]. Virol J, 2015, 12: 129. DOI: 10.1186/s12985-015-0360-y.
[29]	ZHEN J, ZHANG L, PAN J, et al. AIM2 mediates inflammation-associated renal damage in hepatitis B virus-associated glomerulonephritis by regulating caspase-1, IL-1β, and IL-18[J]. Mediators Inflamm, 2014, 2014: 190860. DOI: 10.1155/2014/190860.
[30]	NORDSTRÖM A, BERGMAN J, BJÖRK S, et al. A multiple risk factor program is associated with decreased risk of cardiovascular disease in 70-year-olds: A cohort study from Sweden[J]. PLoS Med, 2020, 17(6): e1003135. DOI: 10.1371/journal.pmed.1003135.
[31]	CIGROVSKI BERKOVIC M, VIROVIC-JUKIC L, BILIC-CURCIC I, et al. Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management[J]. World J Gastroenterol, 2020, 26(21): 2740-2757. DOI: 10.3748/wjg.v26.i21.2740.
[32]	GIESECK RL 3rd, WILSON MS, WYNN TA. Type 2 immunity in tissue repair and fibrosis[J]. Nat Rev Immunol, 2018, 18(1): 62-76. DOI: 10.1038/nri.2017.90.
[33]	LOZANO-RUIZ B, BACHILLER V, GARCÍA-MARTÍNEZ I, et al. Absent in melanoma 2 triggers a heightened inflammasome response in ascitic fluid macrophages of patients with cirrhosis[J]. J Hepatol, 2015, 62(1): 64-71. DOI: 10.1016/j.jhep.2014.08.027.
[34]	GONZÁLEZ-NAVAJAS JM. Inflammasome activation in decompensated liver cirrhosis[J]. World J Hepatol, 2016, 8(4): 207-210. DOI: 10.4254/wjh.v8.i4.207.
[35]	ARRIOLA BENITEZ PC, PESCE VIGLIETTI AI, GOMES M, et al. Brucella abortus infection elicited hepatic stellate cell-mediated fibrosis through inflammasome-dependent IL-1β production[J]. Front Immunol, 2019, 10: 3036. DOI: 10.3389/fimmu.2019.03036.
[36]	CHEN T, CHENG PC, CHANG KC, et al. Activation of the NLRP3 and AIM2 inflammasomes in a mouse model of Schistosoma mansoni infection[J]. J Helminthol, 2019, 94: e72. DOI: 10.1017/S0022149X19000622.
[37]	National Health Commission of the People's Republic of China Medical Administration and Medical Administration. Guidelines for diagnosis and treatment of primary liver cancer (Versoin 2019)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007. 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
[38]	MA XM, QIU YM, MA XX, et al. AIM2 inhibits the progression of hepatocellular carcinoma through the formation and activation of inflammasomes[C]. Chinese Society of Immunology, 2016: 227-228. 马小敏, 邱驭旻, 马晓晓, 等. AIM2通过炎症小体的形成与活化抑制肝细胞肝癌的进展[C]. 中国免疫学会, 2016: 227-228.
[39]	CHEN HT, YANG Z, WU SP. Expression and clinical significance of factor 2 deficiency in peripheral blood mononuclear cell melanoma in primary liver cancer[J/CD]. Electronic Journal of Emerging Infectious Diseases, 2019, 4(3): 149-151, 168. 陈洪涛, 杨智, 吴诗品. 外周血单个核细胞黑色素瘤缺乏因子2在原发性肝癌中的表达及其临床意义[J/CD]. 新发传染病电子杂志, 2019, 4(3): 149-151, 168.
[40]	CHEN SL, LIU LL, LU SX, et al. HBx-mediated decrease of AIM2 contributes to hepatocellular carcinoma metastasis[J]. Mol Oncol, 2017, 11(9): 1225-1240. DOI: 10.1002/1878-0261.12090.
[41]	MA X, GUO P, QIU Y, et al. Loss of AIM2 expression promotes hepatocarcinoma progression through activation of mTOR-S6K1 pathway[J]. Oncotarget, 2016, 7(24): 36185-36197. DOI: 10.18632/oncotarget.9154.
[42]	MARTÍNEZ-CARDONA C, LOZANO-RUIZ B, BACHILLER V, et al. AIM2 deficiency reduces the development of hepatocellular carcinoma in mice[J]. Int J Cancer, 2018, 143(11): 2997-3007. DOI: 10.1002/ijc.31827.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (458) PDF downloads(27)

Expression mechanism and clinical significance of absent in melanoma 2 in liver diseases

DOI: 10.3969/j.issn.1001-5256.2021.10.049

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Expression mechanism and clinical significance of absent in melanoma 2 in liver diseases

DOI: 10.3969/j.issn.1001-5256.2021.10.049

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content